Angina Pectoris Drugs Market Analysis 2016-2022 By Therapeutic Class (Beta Blockers, Calcium Antagonists, Nitrates, Anticoagulants, ACE inhibitors, Ranolazine), Major Markets & Segment Forecasts - ResearchAndMarkets.com

DUBLIN--()--The "Angina Pectoris Drugs Market Analysis, By Therapeutic Class (Beta Blockers, Calcium Antagonists, Nitrates, Anticoagulants, ACE inhibitors, Ranolazine), By Major Markets, And Segment Forecasts, 2016 - 2022" report has been added to ResearchAndMarkets.com's offering.

The global angina pectoris drugs market is expected to be valued at USD 10.6 Billion by 2022

The global angina pectoris market is collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare and availability of effective treatment methods across the emerging markets.

Additionally, the rising prevalence and incidence of angina pectoris is anticipated to fuel the market growth. Chronic stable angina pectoris has a prevalence of 2.0-4.0% in developed markets such as the U.S., the U.K., Germany, France, Italy, Spain and Japan.

The prevalence of angina pectoris rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74, and from 0.1-1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74. The disease symptoms can be managed by following a healthy lifestyle.

Some of the key players operating in this industry are Sanofi, Gilead, AstraZeneca, Pfizer, Eli Lilly, Amgen and GlaxoSmithKline

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

Chapter 4 Global Market Overview

Chapter 5 Pipeline Intelligence

Chapter 6 Company Profiles

Chapter 7 Market Outlook

Companies Mentioned

  • Sanofi
  • Gilead Sciences
  • AstraZeneca
  • Amgen
  • GlaxoSmithKline
  • Eli Lilly
  • Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/gxfj7v/angina_pectoris?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs